Cat.No. | Name | Information |
---|---|---|
M6189 | Ossirene | Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta (IL-1β) converting enzyme. Ossirene abolishes phosphorylation of STAT3 by inhibiting IL-10. Ossirene also inhibits Caspase-1. |
M6223 | Tocilizumab | Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor. Tocilizumab prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab can be used for the research of rheumatoid arthritis and COVID-19. |
M10139 | Anakinra | Anakinra (Raleukin) is an antagonist of recombinant, nonglycosylated human IL-1R. |
M1622 | Secukinumab | Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is the first-in-class anti-IL-17 agent to be used in studies of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. |
M40610 | PF-07275315 | PF-07275315是一种靶向IL-13R,IL-4R和TSLP的三特异性抗体,可用于特应性鼻炎的相关研究。 |
M38978 | Koaburaside | Koaburaside shows antioxidant activity with an IC50 of 9.0 μM for DPPH-free radical scavenging assay. Koaburaside inhibits histamine release and expressions of IL-6 and TNF-α in human mast cells. Koaburaside also effectively inhibits influenza A neuraminidase. |
M38977 | 1,11b-Dihydro-11b-hydroxymedicarpin | Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathways. Medicarpin down-regulates pro-inflammatory cytokines like TNF-α, IL-6 and IL-17A, while up-regulates anti-inflammatory cytokine IL-10 in arthritis (CIA) model of mice. |
M30462 | (S,S)-Formoterol | (S,S)-Formoterol ((+)-Formoterol) is a (S,S)-enantiomer of Formoterol. (S,S)-Formoterol can promote asthma by enhancing IL-4 production in mast cells of the asthmatic airway. |
M30313 | Kansuinine A | Kansuinine A inhibits IL-6-induced Stat3 activation. Kansuinine A possesses antiviral and anticancer activity. |
M30255 | Armillarisin A | Armillarisin A has the potential for the ulcerative colitis (UC) study. Armillarisin A increases IL-4 and lower IL-1β. |
M30224 | SP4206 | SP4206 is an IL-2/IL-2Rα interaction inhibitor. SP4206 binds with high affinity (Kd=70 nM) to IL-2 and blocks binding to its natural receptor IL-2Rα (Kd=10 nM). |
M30189 | NSC61610 | NSC61610 disrupts hIL-18 binding to the ectromelia virus IL-18BP. NSC61610 inhibits hIL-18:ectvIL-18BP complex formation with an IC50 about 6 uM. |
M29647 | IL-17 modulator 1 | IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulator. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis. |
M28690 | SDZ 224-015 | SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM). |
M27782 | Veledimex | Veledimex (INXN-1001), a synthetic analog of the insect molting hormone ecdysone, is an orally active activator ligand for a proprietary gene therapy promoter system. Veledimex can be used to activate certain genes using the ecdysone receptor (EcR)-based inducible gene regulation system, the RheoSwitch Therapeutic System (RTS). Veledimex can cross blood-brain barrier (BBB) in both orthotopic GL-261 mice and cynomolgus monkeys. |
M25338 | Nadunolimab | Nadunolimab is a human monoclonal IgG1 antibody targeting IL1RAP. Nadunolimab blocks IL-1α and IL-1β signaling and triggering antibody-dependent cellular cytotoxicity. Nadunolimab can be used in research of cancer. |
M25292 | Camidanlumab | Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody drug conjugates (ADCs) to research several diseases including lymphoma and leukemia. |
M25282 | Anrukinzumab | Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma. |
M25281 | Enokizumab | Enokizumab (MEDI-528) is a monoclonal antibody targeting to interleukin (IL)-9. IL-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways. |
M25271 | Perakizumab | Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis. |
M25262 | Ordesekimab | Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD). |
M25225 | Elsilimomab | Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA). |
M25216 | Tucotuzumab | Tucotuzumab (Anti-EPCAM Recombinant Antibody) is a protein composed of an IgG1 monoclonal antibody specific for the human Epithelial Cell Adhesion Molecule (EpCAM) antigen, linked to two molecules of IL-2. Tucotuzumab is an immunosuppressant and antineoplastic agent. |
M25173 | Burfiralimab | Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.